Search

Your search keyword '"De la Mora L"' showing total 42 results

Search Constraints

Start Over You searched for: Author "De la Mora L" Remove constraint Author: "De la Mora L"
42 results on '"De la Mora L"'

Search Results

2. Additional file 1 of Increased integrated testing for HIV, hepatitis C and sexually transmitted infections in health care facilities: results from the INTEGRATE Joint Action pilots in Lithuania, Romania and Spain

3. Jalisco: la historia y sus instrumentos

4. Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV.

5. Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and COVID-19 disease among people living with HIV: A cross-sectional population-based study.

6. Epidemiological changes and outcomes of people living with HIV admitted to the intensive care unit: a 14-year retrospective study.

7. Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study.

8. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.

9. [Epidemiology, treatment and prognosis of HIV infection in 2024: A practical review].

10. Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations.

11. Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020.

12. Efficacy and safety of raltegravir plus lamivudine maintenance therapy.

13. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.

14. Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.

15. Increasing of New CA-MRSA Infections Detected in people living with HIV Who Engage in Chemsex in Barcelona: An Ambispective Study.

16. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).

17. Perception of quality of care using patient reported experience measures (PREMs) in a cohort of adults with HIV: A cross-sectional study.

18. Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020.

19. Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years' Experience.

20. PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement.

21. Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life-Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain.

22. Do ART and Chemsex Drugs Get Along? Potential Drug-Drug Interactions in a Cohort of People Living with HIV Who Engaged in Chemsex: A Retrospective Observational Study.

23. Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients.

24. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.

25. Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study.

26. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.

27. Impact of coronavirus disease 2019 epidemics on prevention and care for HIV and other sexually transmitted infections.

29. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.

30. C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19.

31. Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19.

32. Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort.

33. Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study.

34. [Methamphetamine use in chemsex and its consequences on mental health: a descriptive study.]

35. Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study.

36. PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement.

37. Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.

39. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study.

41. Barriers to hepatitis C virus elimination in MSM living with HIV: The high risk of reinfection. Case study: A patient with 6 episodes.

42. Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL-36RN deficiency treated with infliximab: Case report and review of the literature.

Catalog

Books, media, physical & digital resources